Artificial Intelligence In Cancer Treatment: Understanding Current Applications And Future Possibilities

Regulatory, ethical, and validation considerations for AI in cancer treatment

Regulatory frameworks for AI in healthcare typically emphasize evidence of safety, effectiveness, and risk mitigation. Validation pathways often mirror those for diagnostic or decision-support tools and may include retrospective performance evaluation, prospective clinical validation, and post-deployment monitoring. Regulatory expectations can vary by jurisdiction, and developers commonly engage with regulatory guidance early to align study designs and evidence generation plans with applicable requirements. Clear documentation of intended use, limitations, and performance characteristics forms part of regulatory submissions.

Ethical concerns include algorithmic fairness, transparency, and informed consent for data use. Explainable AI techniques that surface key contributing features or highlight uncertainty may assist clinicians in interpreting model outputs, though such explanations do not eliminate the need for clinician oversight. Ethical review boards and institutional governance bodies often assess projects for patient privacy, data minimization, and the potential for disparate impacts across demographic groups. Responsible deployment typically involves monitoring for unintended consequences after models are introduced into practice.

Clinical validation strategies often progress from internal test sets to external validation cohorts and, when appropriate, prospective studies embedded in care pathways. Performance metrics beyond accuracy—such as calibration, decision-curve analysis, and clinical utility assessments—are commonly reported to illustrate how model outputs might influence clinical decisions. Developers and clinical teams often design pilot implementations to measure workflow effects and to identify situations where model guidance aligns or conflicts with standard clinical reasoning.

Post-deployment surveillance is an important aspect of responsible AI use. Models may degrade over time due to changes in practice patterns, equipment, or patient populations, so ongoing monitoring of performance and periodic re-training or recalibration may be necessary. Establishing governance processes that define responsibilities for maintenance, updates, and incident response can help ensure models remain appropriate for their intended context of use. Such processes typically include technical, clinical, and legal stakeholders to manage lifecycle risks.